However, the data supports that circulating mtDNA levels are significantly elevated in the vast majority of NASH and NASH-fibrosis patients who are obese, and TLR9 activation is significantly associated with disease severity in unenriched cohorts of NASH and NASH-fibrosis patients. This evidence concerns the gene TLR9 and metabolic dysfunction-associated steatohepatitis.